Table 3

VDR, CYP27B1 and CYP24A1 and other breast cancer biomarkers expression in carcinomas in situ

VDR

CYP27B1

CYP24A1


+ (%)

- (%)

+ (%)

- (%)

+ (%)

- (%)


ER

+ (%)

46 (35.1)

38 (29.0)

58 (42.3)

29 (21.2)

41 (32.8)

36 (28.8)

- (%)

16 (12.2)

31 (23.7)

33 (24.1)

17 (12.4)

29 (23.2)

19 (15.2)


p value

0.0227

ns

ns


HER2

+ (%)

9 (6.9)

14 (10.7)

18 (13.1)

7 (5.1)

9 (7.2)

12 (9.6)

- (%)

53 (40.5)

55 (42.0)

73 (53.3)

39 (28.5)

61 (48.8)

43 (34.4)


p value

ns

ns

ns


PgR

+ (%)

35 (26.7)

30 (22.9)

49 (35.8)

18 (13.1)

38 (30.4)

22 (17.6)

- (%)

27 (20.6)

39 (29.8)

42 (30.7)

28 (20.4)

32 (25.6)

33 (26.4)


p value

ns

ns

ns


CK5

+ (%)

3 (2.3)

8 (6.1)

7 (5.1)

4 (2.9)

8 (6.4)

4 (3.2)

- (%)

59 (45.0)

61 (46.6)

84 (61.3)

42 (30.7)

62 (49.6)

51 (40.8)


p value

ns

ns

ns


EGFR

+ (%)

1 (0.8)

5 (3.8)

2 (1.5)

5 (3.7)

5 (4.0)

3 (2.4)

- (%)

61 (46.6)

64 (48.9)

89 (65.0)

41 (29.9)

65 (52.0)

52 (41.6)


p value

ns

0.0295

ns


P-cad

+ (%)

4 (3.1)

16 (12.2)

14 (10.2)

12 (8.8)

16 (12.8)

7 (5.6)

- (%)

58 (44.3)

53 (40.5)

77 (56.2)

34 (24.8)

54 (43.2)

48 (38.4)


p value

0.0078

ns

ns


ns: not significant.

Lopes et al. BMC Cancer 2010 10:483   doi:10.1186/1471-2407-10-483

Open Data